Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 29, 2017

View Archived Issues

Engineered SIRPalpha-inhibited, marrow-derived macrophages engulf cancer cells in solid tumors

Plant-produced VLPs of the stabilized PV3 mutant SktSC8 as novel polio vaccine candidate

European Commission approves amendment to Minerva's agreement with Janssen for MIN-202

CANTOS results with canakinumab highlight effects of inflammation on heart attack, cancer risks

AKR1C3 inhibitor BAY-1128688 shows promise for the treatment of endometriosis

Biogen reports data from long-term extension of ongoing phase Ib trial of aducanumab

Gilead Sciences to acquire Kite Pharma

FDA approves expanded use of Faslodex monotherapy in breast cancer

Results presented for KHK inhibitor PF-06835919 for the treatment of NAFLD/NASH

FDA considers the NDA resubmission for Lutathera to be complete

European Commission approves Fotivda for advanced renal cell carcinoma

Bristol-Myers Squibb and Daiichi agree to study Opdivo with DS-8201 in breast and bladder cancers

FDA grants priority review to LJPC-501 NDA

Coherus reports findings from pharmacokinetic study of adalimumab biosimilar CHS-1420

Ophirex licenses sPLA2 inhibitor data from Lilly and Shionogi to support snakebite program

PureTech Health licenses Glyph technology from Monash University

Epizyme patents PRMT inhibitors

BioCryst Pharmaceuticals divulges complement factor D inhibitors

FDA steps up enforcement in area of stem cell therapy and regenerative medicine

EA Pharma discovers novel MAdCAM antagonists

Berg establishes research collaboration with AstraZeneca

New orexin receptor agonists presented by Takeda Pharmaceutical

Shionogi presents new NTRK1 inhibitors

Synlogic and Mirna Therapeutics complete merger

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 15, 2026.
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid
BioWorld
Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...